Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Psoriasis

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register

JAMA Dermatol

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group.

doi: 10.1001/jamadermatol.2020.4202

Psoriasis

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

J Eur Acad Dermatol Venereol.

Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie

doi: 10.1111/jdv.15579.

Psoriasis

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group

doi: 10.1111/bjd.17036.

Psoriasis

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis

JAMA Dermatol.

Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C, British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium.

doi: 10.1001/jamadermatol.2019.1783.

Psoriasis

Drug Survival in Patients with Psoriasis is Associated with the Availability of Biologic Medications

J Eur Acad Dermatol Venereol.

Shalom G, Cohen AD, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L

doi: 10.1111/jdv.16205.

Psoriasis

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Br J Dermatol

Iskandar IYK, Lunt M, Thorneloe RJ, Cordingley L, Griffiths CEM, Ashcroft DM, British Association of Dermatologists Biologics, Immunomodulators Register, Psoriasis Stratification to Optimise Relevant Therapy Study Groups.

doi: 10.1111/bjd.20577

Rheumatoid Arthritis

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register

Rheumatology (Oxford).

Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB

doi: 10.1093/rheumatology/kez671.

Psoriasis

Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study

J Invest Dermatol.

Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CE, Reynolds N, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group and PSORT consortium

doi: 10.1016/j.jid.2018.07.028.

Psoriasis

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

J Eur Acad Dermatol Venereol.

Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP

doi: 10.1111/jdv.14146.

Related content

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis

Drug Survival in Patients with Psoriasis is Associated with the Availability of Biologic Medications

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register

Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature